Comparison of real-time PCR and hemagglutination assay for quantitation of human polyomavirus JC
© Chapagain et al; licensee BioMed Central Ltd. 2006
Received: 04 September 2005
Accepted: 09 January 2006
Published: 09 January 2006
Human polyomavirus JC (JCV), the etiological agent of the disease progressive multifocal leukoencephalopathy (PML) affects immunocompromised patients particularly patients with AIDS. In vitro studies of JCV infection are hampered by the lack of sensitive JCV quantitation tests. Although the hemagglutination (HA) assay has been routinely employed for in vitro quantitation of JCV, its sensitivity is severely limited. We have employed a real-time PCR assay which compares favorably with the HA assay for the in vitro quantitation of JCV. JCV(Mad1), propagated in primary human fetal glial (PHFG) cells in two independent laboratories, was purified and quantitated by the HA assay. Both batches of purified JCV(Mad1) were then serially diluted in Dulbecco's Modified Eagle's Medium to obtain HA titers ranging from 64 to 0.001 HA units (HAU) per 100 μL of virus suspension. DNA was extracted from 100 μL of virus suspension and eluted in 50 μL of buffer, and DNA amplification and quantitation were performed in the Bio-Rad iCycler iQ Multicolor Real-Time PCR Detection System using T-antigen as the target gene. Real-time PCR for quantitation of JCV was sensitive and consistently detected 1.8 × 101 copies of JCV DNA, and as low as 0.001 HAU equivalent of JCV. Moreover, there was a strong linear correlation between the HA assay and the DNA copy number of JCV(Mad1). The intra-run and inter-run coefficients of variation for the JCV standard curve were 0.06% to 4.8% and 2.6% to 5.2%, respectively. Based on these data, real-time PCR can replace the less-sensitive HA assay for the reliable detection, quantitation and monitoring of in vitro JCV replication.
Human polyomavirus JC (JCV), a small, non-enveloped virus with a closed circular double-stranded-DNA genome, is ubiquitous in nature with a seroprevalence of up to 80% among geographically isolated populations [1–3]. JCV was first isolated in 1971 from the brain of a patient with progressive mulifocal leukoencephalopathy (PML) . Most primary JCV infections occur during childhood , and are subclinical. However, JCV remains latent for life and may cause a fatal demyelinating disease, PML, among immunocompromised patients . PML remains a frequent and life-threatening complication of HIV infection and about 3–5% of AIDS patients develop this disease [6, 7]. Factors influencing PML pathogenesis, including modes of JCV transmission, its dissemination from site(s) of initial infection, the mechanism(s) of JCV reactivation, cellular susceptibility, trafficking across the blood-brain-barrier and lytic infection of oligodendrocytes, are still unclear. Efforts to understand the pathogenesis of PML have been hampered by the lack of standard methods for JCV detection and quantitation.
JCV major capsid protein, VP-1, is responsible for red blood cell (RBC) agglutination and traditionally, hemagglutination (HA) and HA inhibition (HAI) assays have been employed for quantitation of JCV [8–14]. However, the HA assay is poorly sensitive and the in vitro quantitation of JC viral load by HA is often impossible. Moreover HA assay cannot be efficiently employed to study JCV replication in various experimental settings including, experiments employing microtiter and transwell plates. Semi-quantitative polymerase chain reaction (PCR) and quantitative real-time PCR have been recently developed and employed for the detection and quantitation of JCV [15–19]. In clinical specimens, real time-PCR has proven to be an important method for monitoring JCV viral load, [15, 20] and is a reliable marker for PML prognosis . However, it is unclear how changes in viral DNA levels are correlated with the virion levels/viral load and no effort has been made to standardize the copy-number equivalent of JCV required in in vitro JCV replication-related experiments. To further our knowledge of PML pathogenesis, uniformly controlled detection and quantitation techniques are essential for in vitro monitoring of JCV replication. In this study, we investigated the relationship between real-time PCR and HA assays for the determination of JC viral load.
JCV(Mad1) was propagated in primary human fetal glial (PHFG) cells and purified in Dr. Duard Walker's laboratory (I) [4, 22, 23] or at the Retrovirology Research Laboratory (RRL) (II), University of Hawaii [13, 24]. PHFG cells, infected with JCV(Mad1) at RRL were harvested on day 30 post infection, subjected to three freeze-thaw cycles, disrupted by sonication at 100 watt for 1 min on ice using an Autotune series high-intensity ultrasonic processor, and incubated with 0.25% deoxycholic acid at 37°C for 1 hr. Cellular debris was removed by centrifugation at 5,000 rpm (1,960 × g) for 30 min and the supernatant was layered on 30% sucrose (w/w) and centrifuged at 35,000 rpm in a Beckman SW 55Ti rotor using a Beckman LE-80K ultracentrifuge (Beckman Coulter, Inc., Fullerton, CA). The supernatant was decanted and the pellet was suspended in Dulbecco's Modified Eagle's Medium (DMEM) and stored at -80°C. JCV titers were determined by the HA assay as described elsewhere [3, 10]. Briefly, human type O blood was centrifuged at 2,500 rpm for 10 min at 4°C. RBC were then washed twice and suspended in Alsever's buffer (20 mM sodium citrate, 72 mM NaCl, 100 mM glucose, pH 6.5 adjusted with acetic acid) at a final concentration of 0.5%. Serial two-fold dilutions of virus suspensions were prepared in Alsever's buffer and 50 μL of viral suspension and an equal volume of RBC were added into each well of a 96-well "U" bottom microtiter plate and incubated at 4°C for 3–6 hr. The HA titer was the reciprocal of the final dilution of virus suspension that agglutinated RBC. The end point dilution was considered 1 hemagglutination unit (HAU).
Both batches of JCV(Mad1) (I and II) were serially diluted two-fold (64 HA to 1 HA) and then 10-fold (1 HA to 0.001 HA) in DMEM, to obtain HA titers ranging from 64 HAU to 0.001 HAU per 100 μL of the suspension. DNA was extracted from 100 μL of the above suspension containing known HAU of JCV using the QIAprep® Spin Miniprep kit (Cat No. 27106), according to the manufacturer's instructions and DNA was eluted in 50 μL of elution buffer . JCV DNA amplification and quantitation were performed in the Bio-Rad iCycler iQ™ Multicolor Real-Time PCR Detection System using 2 μL of 1:10 diluted template DNA, Bio-Rad 2X iQ™ SYBER® Green supermix and 12.5 pmol each of forward and reverse primers specific for the JCV T-antigen gene [JCT-1 (Forward: 5' AGA GTG TTG GGA TCC TGT GTT TT 3'; JCT-2 (Reverse) 5' GAG AAG TGG GAT GAA GAC CTG TTT 3'] (GeneBank Accession No. J02226)  in a final reaction volume of 20 μL. Thermal cycling was initiated with a first denaturation step of 10 min at 95°C, followed by 40 cycles of 95°C for 10 sec and 60°C for 15 sec and the amplification fluorescence was read at 60°C at the end of the cycle. Real-time PCR amplification data were analyzed using the Bio-Rad iCycler iQ™ Multicolor Real-Time PCR Optical System Software Version 3.1. A standard curve for the quantitation of JCV was constructed using serial dilutions of the linearized JCV(Mad1) plasmid. The dynamic range of detection was determined by preparing 10-fold serial dilutions of JCV plasmid in the range of 10 pg to 1 fg, that represented 1.8 × 105 to 1.8 × 101 copies of JCV DNA, respectively. All experiments were done twice and samples were run in triplicate each time. Copies of JCV DNA in experimental samples were calculated from the standard curve and were expressed as copies of viral DNA per 100 μL of virus suspension. The reliability of real-time PCR was defined by calculating coefficients of variation of Ct values of replicates of standard curve dilutions [21, 26].
There was a strong linear correlation between the HA assay and the DNA copy number of JCV(Mad1) either propagated by Dr. Walker (I, r2 = 1.0) or propagated at the RRL (II, r2 = 0.95) (Fig 1C). JCV(Mad1) obtained from two different sources yielded very similar DNA T-antigen gene copy numbers from samples containing the same HAU of JCV. However, the difference was more pronounced when the suspension contained less than 4 HAU of JCV. This difference might have resulted from the presence of different proportions of either the empty virions or naked DNA. The ratio of empty virions and naked JCV DNA present in virus suspension may be affected by several factors including the virus strain, cell type used to propagate JCV, virus isolation procedures as well as time of harvesting the infected cells. Moreover, the less than two-fold difference in JCV copy numbers in two sources of virus may simply be the result of the less sensitive HA assay. The HA assay produced similar results when the virions in any two samples differed by less than two-fold.
Our data demonstrate that real-time PCR is a sensitive and reliable method for in vitro quantitation of JCV. In vitro measurement of JCV DNA levels was highly reproducible over a large dynamic range, and real-time PCR was more reliable than the HA assay for in vitro calculation of initial virus inoculum and replicated virus. In the future, quantitative real-time PCR can be employed to study in vitro efficacy of several potential therapeutic agents against JCV as well as to quantitate JCV trafficking across the blood-brain-barrier using an in vitro model. Real-time PCR detects as low as 0.001 HAU equivalent of JCV, eliminates the variability traditionally associated with the HA assay, and thus could reliably replace the HA assay employed for JCV replication in in-vitro pathogenesis studies.
We thank Dr. Richard Frisque for the generous gift of JCV(Mad1) and Dr. Eugene Major for his kind gift of positive controls to conduct the JCV HA assay. We thank Dr. Richard Frisque and Dr. Richard Yanagihara, for reviewing the manuscript, and for critical discussions throughout this study. This study was supported by grants from the National Institute of Neurological Disorders and Stroke (S11 NS041833 and U54 039406), and from the National Center for Research Resources (G12 RR003061 and P20 RR018727), National Institutes of Health.
- Rollison DE, Helzlsouer KJ, Alberg AJ, Hoffman S, Hou J, Daniel R, Shah KV, Major EO: Serum antibodies to JC virus, BK virus, simian virus 40, and the risk of incident adult astrocytic brain tumors. Cancer Epidemiol Biomarkers Prev 2003, 12: 460-463.PubMedGoogle Scholar
- Kim HS, Henson JW, Frisque RJ: Transcription and replication in the human polyomaviruses. In Human Polyomaviruses. Edited by: Khalili K and Stoner GL. New York, Wiley-Liss, Inc.; 2001:73-126.View ArticleGoogle Scholar
- Padgett BL, Walker DL: Prevalence of antibodies in human sera against JC virus, an isolate from a case of progressive multifocal leukoencephalopathy. J Infect Dis 1973, 127: 467-470.View ArticlePubMedGoogle Scholar
- Padgett BL, Walker DL, ZuRhein GM, Eckroade RJ, Dessel BH: Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet 1971, 1: 1257-1260.View ArticlePubMedGoogle Scholar
- Padgett BL, Walker DL, ZuRhein GM, Hodach AE, Chou SM: JC Papovavirus in progressive multifocal leukoencephalopathy. J Infect Dis 1976, 133: 686-690.View ArticlePubMedGoogle Scholar
- Koralnik IJ: New insights into progressive multifocal leukoencephalopathy. Curr Opin Neurol 2004, 17: 365-370.View ArticlePubMedGoogle Scholar
- Berger JR: Progressive multifocal leukoencephalopathy in acquired immunodeficiency syndrome: explaining the high incidence and disproportionate frequency of the illness relative to other immunosuppressive conditions. J Neurovirol 2003, 9: 38-41.View ArticlePubMedGoogle Scholar
- Seth P, Diaz F, Tao-Cheng JH, Major EO: JC virus induces nonapoptotic cell death of human central nervous system progenitor cell-derived astrocytes. J Virol 2004, 78: 4884-4891.PubMed CentralView ArticlePubMedGoogle Scholar
- Hara K, Sugimoto C, Kitamura T, Aoki N, Taguchi F, Yogo Y: Archetype JC virus efficiently replicates in COS-7 cells, simian cells constitutively expressing simian virus 40 T antigen. J Virol 1998, 72: 5335-5342.PubMed CentralPubMedGoogle Scholar
- Neel JV, Major EO, Awa AA, Glover T, Burgess A, Traub R, Curfman B, Satoh C: Hypothesis: "Rogue cell"-type chromosomal damage in lymphocytes is associated with infection with the JC human polyoma virus and has implications for oncopenesis. Proc Natl Acad Sci U S A 1996, 93: 2690-2695.PubMed CentralView ArticlePubMedGoogle Scholar
- Knowles WA, Luxton RW, Hand JF, Gardner SD, Brown DW: The JC virus antibody response in serum and cerebrospinal fluid in progressive multifocal leucoencephalopathy. Clin Diagn Virol 1995, 4: 183-194.View ArticlePubMedGoogle Scholar
- Knowles WA, Pipkin P, Andrews N, Vyse A, Minor P, Brown DW, Miller E: Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol 2003, 71: 115-123.View ArticlePubMedGoogle Scholar
- Akatani K, Imai M, Kimura M, Nagashima K, Ikegami N: Propagation of JC virus in human neuroblastoma cell line IMR-32. J Med Virol 1994, 43: 13-19.View ArticlePubMedGoogle Scholar
- Hou J, Major EO: The efficacy of nucleoside analogs against JC virus multiplication in a persistently infected human fetal brain cell line. J Neurovirol 1998, 4: 451-456.View ArticlePubMedGoogle Scholar
- Ryschkewitsch C, Jensen P, Hou J, Fahle G, Fischer S, Major EO: Comparison of PCR-southern hybridization and quantitative real-time PCR for the detection of JC and BK viral nucleotide sequences in urine and cerebrospinal fluid. J Virol Methods 2004, 121: 217-221.View ArticlePubMedGoogle Scholar
- Whiley DM, Mackay IM, Sloots TP: Detection and differentiation of human polyomaviruses JC and BK by LightCycler PCR. J Clin Microbiol 2001, 39: 4357-4361.PubMed CentralView ArticlePubMedGoogle Scholar
- Beck RC, Kohn DJ, Tuohy MJ, Prayson RA, Yen-Lieberman B, Procop GW: Detection of polyoma virus in brain tissue of patients with progressive multifocal leukoencephalopathy by real-time PCR and pyrosequencing. Diagn Mol Pathol 2004, 13: 15-21.View ArticlePubMedGoogle Scholar
- Watzinger F, Suda M, Preuner S, Baumgartinger R, Ebner K, Baskova L, Niesters HG, Lawitschka A, Lion T: Real-time quantitative PCR assays for detection and monitoring of pathogenic human viruses in immunosuppressed pediatric patients. J Clin Microbiol 2004, 42: 5189-5198.PubMed CentralView ArticlePubMedGoogle Scholar
- Verma S, Ziegler K, Ananthula P, Co JKG, Frisque RJ, Yanagihara R, Nerurkar VR: JC virus induces altered patterns of cellular gene expression: Interferon-inducible genes as major transcriptional targets. Virology 2005.Google Scholar
- Rollison DE, Utaipat U, Ryschkewitsch C, Hou J, Goldthwaite P, Daniel R, Helzlsouer KJ, Burger PC, Shah KV, Major EO: Investigation of human brain tumors for the presence of polyomavirus genome sequences by two independent laboratories. Int J Cancer 2005, 113: 769-774.View ArticlePubMedGoogle Scholar
- Bossolasco S, Calori G, Moretti F, Boschini A, Bertelli D, Mena M, Gerevini S, Bestetti A, Pedale R, Sala S, Lazzarin A, Cinque P: Prognostic significance of JC virus DNA levels in cerebrospinal fluid of patients with HIV-associated progressive multifocal leukoencephalopathy. Clin Infect Dis 2005, 40: 738-744.View ArticlePubMedGoogle Scholar
- Padgett BL, Rogers CM, Walker DL: JC virus, a human polyomavirus associated with progressive multifocal leukoencephalopathy: additional biological characteristics and antigenic relationships. Infect Immun 1977, 15: 656-662.PubMed CentralPubMedGoogle Scholar
- Osborn JE, Robertson SM, Padgett BL, Walker DL, Weisblum B: Comparison of JC and BK human papovaviruses with simian virus 40: DNA homology studies. J Virol 1976, 19: 675-684.PubMed CentralPubMedGoogle Scholar
- Liu CK, Hope AP, Atwood WJ: The human polyomavirus, JCV, does not share receptor specificity with SV40 on human glial cells. J Neurovirol 1998, 4: 49-58.View ArticlePubMedGoogle Scholar
- Ziegler K, Bui T, Frisque RJ, Grandinetti A, Nerurkar VR: A rapid in vitro polyomavirus DNA replication assay. J Virol Methods 2004, 122: 123-127.View ArticlePubMedGoogle Scholar
- Reed GF, Lynn F, Meade BD: Use of coefficient of variation in assessing variability of quantitative assays. Clin Diagn Lab Immunol 2002, 9: 1235-1239.PubMed CentralPubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.